Rezolute, Inc.

RZLT Healthcare Biotechnology

In the quarter to June 2026, EPS grew 23.1% and free cash flow grew 40.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

3.58 0.32 −8.21%
Market cap
$377.2M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(59.04%) (81.73%) (74.02%) (59.23%)

+8 more TTM periods

ROA
(53.82%) (74.01%) (67.21%) (54.73%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(78.26%) (71.23%) (67.04%) (53.39%)
Free Cash Flow per Share
(0.62) (0.71) (0.74) (0.68)
Free Cash Flow
(64.63) (73.48) (77.15) (70.49)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Oct 2026